3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
7
Not yet recruiting
2
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
3
Breast Neoplasms
3
Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcopenia
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Obesity
1
Neoplasm Metastasis
1
Hematopoietic and Lymphatic System Neoplasm
1
Fatigue
1
Cholangiocarcinoma
1
Interventions
enzalutamide
33
Abiraterone Acetate
28
apalutamide
25
Radiotherapy
25
Prednisone
25
Magnetic Resonance Spectroscopy
25
Androgen Antagonists
24
Leuprolide
21
Radiosurgery
19
darolutamide
18
Docetaxel
17
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Gonadotropin-Releasing Hormone
14
gallium 68 PSMA-11
12
Specimen Handling
12
Goserelin
12
pembrolizumab
11
Radiotherapy, Intensity-Modulated
11
Radiation
11
bicalutamide
10
abiraterone
10
Pluvicto
10
Carboplatin
9
Brachytherapy
9
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
9
relugolix
8
luprolide acetate gel depot
8
Standard of Care
8
Nivolumab
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Prostatic Neoplasms
×
Resistance Training
×
Clear all
NCT02730338
2024-11-27
INTERVAL
Movember Foundation
Phase NA
Active not recruiting
866 enrolled